SCHEMBL5565378

SCHEMBL5565378

Cc1ccccc1CN(C)C(=O)CC(Cc1ccccc1F)NC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.48
CTSK P43235 1/20 0.48
PTPN1 P18031 1/20 0.41
SCN9A Q15858 12/20 0.41
RIPK1 Q13546 1/20 0.41
ATM Q13315 1/20 0.40
JAK2 O60674 2/20 0.38
S1PR4 O95977 2/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
XBP1 P17861 2/20 0.38
HTT P42858 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HSP90AA1 P07900 1/20 0.38
THRB P10828 1/20 0.38
KMT2A Q03164 2/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8279767 1.00 CTSS (0.48) CTSSCTSKPTPN1SCN9ARIPK1
SCHEMBL5561946 0.94 CTSS (0.52) CTSSCTSKPTPN1SCN9ARIPK1
SCHEMBL5561944 0.94 CTSS (0.52) CTSSCTSKPTPN1SCN9ARIPK1
SCHEMBL5566571 0.87 CTSS (0.46) CTSSCTSKPTPN1SCN9ARIPK1
SCHEMBL8278794 0.87 CTSS (0.46) CTSSCTSKPTPN1SCN9ARIPK1
SCHEMBL4665020 0.83 CTSS (0.52) CTSSCTSKPTPN1SCN9AATM
SCHEMBL8272558 0.83 CTSS (0.52) CTSSCTSKPTPN1SCN9AATM
SCHEMBL4896150 0.81 CTSS (0.60) CTSSCTSKPTPN1SCN9AATM
SCHEMBL17015 0.81 CTSS (0.60) CTSSCTSKPTPN1SCN9AATM
SCHEMBL3997764 0.81 CTSS (0.60) CTSSCTSKPTPN1SCN9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197522-A1 Dpp-iv inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-08-23 US disclosed
EP-1758861-A1 DPP-IV INHIBITORS Santhera Pharmaceuticals (Schweiz) AG (CH) 2007-03-07 EP disclosed
EP-1593671-A1 DPP-IV inhibitors Graffinity Pharmaceuticals AG (DE) 2005-11-09 EP disclosed
WO-2005095343-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197522-A1 Dpp-iv inhibitors DPP7, DPP4, DPP3 CTSS 261/4885CTSK 185/4885PTPN1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.